{"name":"Teva Neuroscience, Inc.","slug":"teva-neuroscience-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Rasagiline mesylate with Levodopa","genericName":"Rasagiline mesylate with Levodopa","slug":"rasagiline-mesylate-with-levodopa","indication":"Parkinson's disease (motor symptom management)","status":"marketed"},{"name":"Rasagiline mesylate with Requip","genericName":"Rasagiline mesylate with Requip","slug":"rasagiline-mesylate-with-requip","indication":"Parkinson's disease (motor symptom management)","status":"marketed"},{"name":"Rasagiline mesylate plus Mirapex","genericName":"Rasagiline mesylate plus Mirapex","slug":"rasagiline-mesylate-plus-mirapex","indication":"Parkinson's disease","status":"marketed"}]}],"pipeline":[{"name":"Rasagiline mesylate with Levodopa","genericName":"Rasagiline mesylate with Levodopa","slug":"rasagiline-mesylate-with-levodopa","phase":"marketed","mechanism":"Rasagiline is a monoamine oxidase B (MAO-B) inhibitor that increases dopamine levels in the brain, while levodopa is converted to dopamine to replace depleted neurotransmitter in Parkinson's disease.","indications":["Parkinson's disease (motor symptom management)"],"catalyst":""},{"name":"Rasagiline mesylate with Requip","genericName":"Rasagiline mesylate with Requip","slug":"rasagiline-mesylate-with-requip","phase":"marketed","mechanism":"Rasagiline is a monoamine oxidase B (MAO-B) inhibitor that increases dopamine levels in the brain, while ropinirole (Requip) is a dopamine D2/D3 receptor agonist, together enhancing dopaminergic signaling for Parkinson's disease management.","indications":["Parkinson's disease (motor symptom management)"],"catalyst":""},{"name":"Rasagiline mesylate plus Mirapex","genericName":"Rasagiline mesylate plus Mirapex","slug":"rasagiline-mesylate-plus-mirapex","phase":"marketed","mechanism":"This combination pairs a monoamine oxidase B inhibitor with a dopamine agonist to enhance dopaminergic signaling in the brain for Parkinson's disease management.","indications":["Parkinson's disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-02-20","type":"regulatory","source":"GlobeNewswire","summary":"U.S. Food and Drug Administration (FDA) Accepts Teva’s New - GlobeNewswire","headline":"U.S. Food and Drug Administration (FDA) Accepts Teva’s New","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNQ21wOVM5MGs2QzBGMHFoNWtNUFZHQ01OaEZURDNveDJpTmU5YjZtbF9YT0FpbGs4ZjlKVDVJbFAzRmVzVG1UeUVUVTJreTdlSThSdDVQTV9uT2p4OE9QMXN1NFJxRlVIWlF4X3N1bWEwSmJyUlVaTlBSZWlRRktaR2N0Z2wwQ3lJNDhselBoMF9FcTBFajFHQXlyT0J0bzJlWW80OGlZTFJLWEQwcFk5cXBB?oc=5","date":"2026-02-03","type":"pipeline","source":"TradingView","summary":"TEVA PHARMACEUTICAL INDUSTRIES LTD SEC 10-K Report - TradingView","headline":"TEVA PHARMACEUTICAL INDUSTRIES LTD SEC 10-K Report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxNWFBxcmdsanZrRkhOMlZkODA1ZVNuVTFWOENRdUdFemYzUWRWcWRjbzBUNzhwYTFvVDhmcXlwcHM5enRxVzdUQ3Q1UVpDZGVtVHYtMmxhR0ItR19LUm9NWmp0cnE0NklpWDY4UjFYa1dkazFyV3piRGtHZ2RDRGhWaTlWcVlWMThaTUhBVVFGVVBxcGZIemFBdHUydjQ0Qm1NdDBqbDVWNXJaT21QVXBMc01jU2RZNVNfLW9PaVBzc0ticmo5clJJeHFEV0pPYWhQVDh2TFNqcjNWNnljWm9VbXgxdktTcGZMZXA2SHVHZw?oc=5","date":"2026-01-14","type":"regulatory","source":"Quiver Quantitative","summary":"Teva Pharmaceuticals Announces FDA Approval of AJOVY for Pediatric Migraine Prevention Following Positive SPACE Trial Results - Quiver Quantitative","headline":"Teva Pharmaceuticals Announces FDA Approval of AJOVY for Pediatric Migraine Prevention Following Positive SPACE Trial Re","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxNaFZDZ3Z0ZGlFb0hKM2Z4MjluNmd0WEpBYjNiNUVyMmtJTjZpZDB3WGNvM2wwMDZpMmFVRkx2LVV0Z2VoZ1VDLVJGVUlheHRnZGR5TTZzdFlYMVRiczNqbjRUY1A2OV85LUQyODlrQlBMYzBHVHpUa2xfNk5UYVNDREZRUlAyd0s1NXNNU0FpM2hJRklTRVl0X1dqZll3TlAycmxLYzU1eTY1SE1ucVE3Q1NfUHdEcmxtakJqVHlhdVJWZ1RyWHhFT0ZyZUdkNjFlU190VmIya3BtMm5KVWM3NEd4UTVXRmJVNkU5TlBSRlFKRjZyMVF4Qm5VZ01WTE9STllJbkRjSENRMHdIR081NUQ0akxMMkhkV0Q5WUFXOEtjVzI4LXNhMm1R?oc=5","date":"2025-11-03","type":"pipeline","source":"GlobeNewswire","summary":"Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive - GlobeNewswire","headline":"Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxNa3VDUWFDTHJ0dEFRdHZBZTk4cUtfckJtdHRZWUlMWHZPZjlLUHVyZVlwRU9lLTZxdDNHc3BVdmYwNkk0eGgxUEdiZDFMWVR2UlcxV21mdVBDYTlua0pzM0ZlX05nUUVqZEs0SldVeTc2QnQ2TWV5NHZJb0stQ2dIQ2VQeFU0b3FZU1IyOGdSYldHVmlpMzVrajdRTTFCcU40REY1djlRM0xLOGhRX1ljTDYySVNUcjRwMFU5UXRadl9JM0l3djBMNUxXZ2x4OUdpV2Z6NDlVeDkwZ1BMSkl1dmljX1oxdnJuSHIxdG41SkdDZGRmMFNIajNWNA?oc=5","date":"2025-10-10","type":"regulatory","source":"Quiver Quantitative","summary":"Teva Pharmaceuticals Announces FDA Approval of UZEDY® (risperidone) for Maintenance Treatment of Bipolar I Disorder in Adults - Quiver Quantitative","headline":"Teva Pharmaceuticals Announces FDA Approval of UZEDY® (risperidone) for Maintenance Treatment of Bipolar I Disorder in A","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOOTV6VEtLUWJ5dkcyekhDQzNfMlRyMm1jSG5raWxndDJDRk1HSUJpLWNqTVJhZHN6ckxWZHdoNVEyTGNaNm42cTRqeXl0UktYOTdSS0tsU3dUWUJhcWFpZHpndDBsY3YtSk9OSWZmTnFpZlpDd2RqaTFiYTdnYURydQ?oc=5","date":"2025-09-09","type":"regulatory","source":"Yahoo Finance","summary":"Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy - Yahoo Finance","headline":"Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQLUtBTl95UGxWb2FMNlFRbjFRcWNsQ0paUGYxZVFvTXNaQXl5UGt3RHdld2hXcGZOMEQ0NnRSNUZDVTlURzJ3RkpIa05XU2MzZkRLRDI1WkJ6bjc0WFBjeVc3LUw0eDRkREx1VnFVSnl0VXg3NkZ2WXBUY0xtZkRQYkk4U0E?oc=5","date":"2025-02-11","type":"pipeline","source":"Pharmaceutical Executive","summary":"The Teva Turnaround: Steering a Company Comeback - Pharmaceutical Executive","headline":"The Teva Turnaround: Steering a Company Comeback","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNclA2ejJfdDAySjBvc28zMUNGVGl1Q1UxZnExVEluMkJRMUQ0Qzg4MlRWdUc0ZW90aGo5UU9XRll6OHFlck51TUpCV2xuclNDQURYMWtyd3lMbHltaHQ5RGVEa3ZHWEtWMDlpdDFmSFdiVmREQ1JOWUk0U1BkUlFhMldhTUpHdlA5c25kTUxXamYzTTJ6NjUzcGo4TkJfSmJCZHF5OG44Rnp6dUU?oc=5","date":"2023-11-13","type":"pipeline","source":"Fierce Pharma","summary":"Teva draws $100M from Royalty funding to bankroll long-acting schizophrenia drug - Fierce Pharma","headline":"Teva draws $100M from Royalty funding to bankroll long-acting schizophrenia drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNYW5FcWxBSHdJYmVqcXoyN3NJRU1nTE5jZlc2OEdqU3BPT05xbWZheWNncElhdW91VUlDa0RHX1hOa0JOYUdkcE9yQjhEUjZsVlpSVmRKbjlHTDdjeTh5Z1hLNUphbmszenFRYnZvZUVyUVlzOUNVR1duLTliYlpnZkdRWmhvd253SnJBYmd3bExfNWNFVTFySm8tY2RCaXA1RlhEaF9QTWtzVU40LUNUVlg2a2hxSGM?oc=5","date":"2023-05-10","type":"earnings","source":"Reuters","summary":"Teva Pharm bets on neurology drugs for growth as Q1 profit misses - Reuters","headline":"Teva Pharm bets on neurology drugs for growth as Q1 profit misses","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxNYkh2Y01mVUp2TlBWXzlMdEdQc0JZby1DRVo1bVVEdlM3MERHN1NSUVNKQ19GSlRxd09BQ0tpREhDcWFPQnhTTnBOYVJsZWd6dS1ZOHpSZjV0N0d3TGtVNGprNmFGMTBMVDJMZkNhNGlmT3pOb09aX0dwdDVCRjFPUDFOem1YRS0ySVB4OFNkWkpoTktkUVVwOEx5MFRwRWVQVnlnZmFSUENDVHJBeE5GaER0ZjB0ZS1hb09RM0FkYndjbDhPTF9tcHYwM2RBRi1Tc0dRRGlzb041LVF3ck14RlYxZE5pdWZJbHFONjVNbngyeXc3R1BhRlBXSVpNdmpwUFZqY2cwZmUyQ0dh?oc=5","date":"2021-05-17","type":"pipeline","source":"BioSpace","summary":"Teva Launches 'It's Not OK - It's TD' National Television Advertising Campaign to Increase Awareness of Tardive Dyskinesia and AUSTEDO® (deutetrabenazine) tablets - BioSpace","headline":"Teva Launches 'It's Not OK - It's TD' National Television Advertising Campaign to Increase Awareness of Tardive Dyskines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNejZlSU1XbkZvbFBsU05ITlJMejgza050VE52NXVQTXVGenhTbThVa0lhQWl1eDRfQWVKSi1CdFNaSlRLNzNzTExpZkpXellSN3V3R0NiLWdwejJRSEI5UEZ5LVVjTFhsbnRaS29uYzVUSkVmOGNOb3lVSnY5SERndlNVRl9JRDRiU0dsLU1SUQ?oc=5","date":"2020-08-18","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Feds accuse Teva of $300M in kickbacks for MS drug - drugdiscoverytrends.com","headline":"Feds accuse Teva of $300M in kickbacks for MS drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOWFBaX2JBN2Q3TWVXSC1fTmh1eFR4UFRGeHdjYm1MZEtqY0VveV9tSVZTWWZtd1hNa05iT1hHcExmVDk2NVBpSjJ6ZmxONW8tZDR0aXlpMzFjVDltTllQYmdoMS16dEVWbmJYT2FwdGpfeENQck5TelAxQmxJYU1QMEZkcXBHZ9IBiwFBVV95cUxPRTB6UXVpaFVrcjlpU1Fxd1BqWEhjYmRtQ0l6T0RoZWw0bXNDMl9USHlwOE5RSDVIRW10UHlZMWZua2pKTVd0bXUtbVpSM1FQT0hrLUh5VFdoN3JQZ0NaOTRLbWxDek9HdzBzdzU2OHd3czh1OUMtUnBzdUVMM0RMRU1qeWtndDFqNkQ0?oc=5","date":"2020-08-18","type":"pipeline","source":"Fox Business","summary":"DOJ accuses drugmaker Teva of illegal kickbacks to inflate prices - Fox Business","headline":"DOJ accuses drugmaker Teva of illegal kickbacks to inflate prices","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}